Syndax Pharmaceuticals, Inc.
Dennis Podlesak (Director) sells SNDX shares
About this filing
Syndax Pharmaceuticals, Inc. (SNDX) filed Form 4 (insider transaction) with the SEC on Oct 30, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Dennis Podlesak · Director
Rule 10b5-1 plan · adopted Oct 31, 2026
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | M · exercise or conversion of a derivative | +8,000 | $11.81 | $94,480.00 | 247,763 | Direct |
| Oct 29, 2026 | S · open-market saleFootnotes F1, F2 | −8,000 | $14.21 | $113,716.00 | 239,763 | Direct |
| Oct 29, 2026 | M · exercise or conversion of a derivativeStock Options (Right to buy)Footnotes F3 | −8,000 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to Octobre 31, 2026. Following the sales reported in this Form 4, the Reporting Person has a total of 127,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.
- F2 The sale prices ranged from $14.00 to $14.59.
- F3 This option is fully vested.
More SNDX filings
- 144
Filed Oct 29, 2026
- SC 13G
Filed Aug 7, 2026
- 10-Q
Filed Aug 4, 2026
- 8-K
Filed Aug 4, 2026
- 8-K
Filed Jul 14, 2026
- 4
Filed Jul 9, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.